to MI. A large number of studies have tried to shed some light on the possible association between the ACE gene insertion/deletion (I/D) polymorphism and the risk of MI.
M yocardial infarction (MI) is the leading cause of death in men and women, 1 and its etiology involves both genetic and environmental factors. 2, 3 During the last decade, the angiotensin-converting enzyme (ACE) gene became one of the most studied candidate genes in relation Angiotensin-converting enzyme (ACE) gene 2350G>A polymorphism has the most significant effect on plasma ACE concentrations. But the association between this polymorphism and myocardial infarction (MI) is presently unknown. We carried out a case-control study in the Chinese Han population. ACE2350G>A genotypes of 231 patients with MI and 288 healthy controls were detected by PCR-RFLP. Differences in frequencies of ACE genotypes and alleles and their associations with clinical features were assessed. The distribution of the ACE2350G>A genotypes (GG, GA, and AA) was 20.78%, 51.08%, and 28.14% in the MI group and 31.60%, 46.53%, and 21.87% in controls, respectively (P = .0167).The frequency of the A allele in the MI group was significantly higher than that in controls (53.68% vs 45.14%, P = .0062). The A allele carriers (GA + AA genotypes) had approximately 2-fold increased risk of MI when compared with the GG genotype (odds ratio = 1.76; 95% confidence interval = 1.24-3.52). There were no significant differences among the 3 genotypes in plasma levels of lipids, apolipoproteins, high-sensitivity C-reactive protein, and soluble CD40 ligand in either the MI group or the control group (P > .05). No statistical difference was observed between ACE2350G>A polymorphism and severity of the coronary lesions (P > .05). These results suggest that ACE2350G>A polymorphism is associated with acute MI, and A allele carrier is an independent risk factor for acute MI in the Chinese Han population. difference is strongly influenced by the I/D polymorphism. 9, 10 Patients homozygous for the D allele are characterized by elevated plasma levels of ACE compared with patients homozygous for the I allele. 11 However, its functional role has been debated. Probably, this polymorphism is in strong linkage disequilibrium (LD) with another functional mutation within the gene. 12 Recently, a genome-scan analysis by The Framingham Heart Study found strong evidence for a quantitative-trait locus on chromosome 17, which was close to the ACE gene and was linked to blood pressure. 13 Among the 13 polymorphisms of the ACE gene recently reported, a dimorphism in exon 17, 2350G>A, has the most significant effect on plasma ACE concentration. 14 Based on these findings we carried out a casecontrol study of ACE gene 2350G>A polymorphism for a putative association with MI and with plasma/ serum levels of high-sensitivity C-reactive protein (hs-CRP) and soluble CD40 ligand (sCD40L) in Chinese. The present study is aimed at establishing whether the ACE2350G>A polymorphism is a genetic marker of MI.
Participants and Methods

Participants
A total of 231 patients who survived an acute MI were eligible for this study. They were enrolled from the First Affiliated Hospital of Soochow University (Suzhou, Jiangsu, China). All diagnoses in this study followed strict diagnostic rules based on signs, symptoms, electrocardiograms, and cardiac enzymes. Those with congenital heart disease, cardiomyopathy, valvular disease, and renal or hepatic disease were excluded, and 288 age-and gender-matched individuals served as controls. The controls were judged to be free of coronary heart disease based on history, clinical examination, electrocardiography, and the Rose questionnaire. All study participants were unrelated and were Han Chinese. Details of medical history were obtained from all participants using a standardized questionnaire, together with information of drug intake and cigarette smoking. Blood pressure, height, weight, and waistline were measured by trained physicians or nurses according to standardized protocols. The study was approved by the Medical Ethics Committee of Soochow University, and written informed consent was obtained from all participants.
Selective Coronary Angiography
Of the 231 acute MI patients 165 (71.43%) underwent selective coronary angiography. Severity of the coronary artery disease was assessed according to the following criteria: (1) number of vessels affected (single-vessel or multi-vessel disease) 15 and (2) morphological characteristics of the atherosclerotic plaque (A: proximal concentric lesion < 10 mm; B1: eccentric lesion between 10 and 20 mm, with moderate proximal tortuosity; B2: eccentric lesion between 10 and 20 mm, with moderate distal, ostial tortuosity or tortuosity in the bifurcations; C: lesion > 20 mm or total occlusion). 16 
Laboratory Measurements
Venous blood samples were obtained after at least a 10-hour overnight fast and then centrifuged at 2500 rpm for 30 minutes at 4°C. Plasma/serum and the blood cell portion were pipetted from each sample, respectively, and then immediately stored at −80°C until analysis and till DNA could be extracted. Once a sufficient number of samples were collected, they were removed from the freezer and thawed to room temperature. The plasma samples were measured using the reagents purchased from Daiichi Pure Chemicals Company (Tokyo, Japan) on Olympus AU 1000 automated chemistry analyzer (Tokyo, Japan). Plasma levels of total cholesterol (TC), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), and triglycerides (TG) were determined using standard enzymatic colorimetric methods. ApoAI and ApoB were assayed by immunoturbidimetric assay. Measurement of hs-CRP was performed on serum using particle-enhanced immunoturbidimetric latex agglutination methodology (Dade Behring, Newark, DE). 17 Serum level of sCD40L was measured using an electrochemiluminescence enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN).
Genetic Analyses
Genomic DNA was extracted from peripheral blood leukocytes by the salting-out method, 18 with minimal modifications. The 2350G>A genotypes in ACE were determined using the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) as described previously, 14 with modification by introducing a mismatch guanine at the 3' end of the primer sequence, resulting in the amplification of a BstU1 restriction site. A 122 bp PCR amplification product was generated from genomic DNA using the following primers: 5'-CTGACGAATGTGATGGCCGC-3' (sense) and 5'-TTGATGAGTTCCACGTATTTCG-3' (antisense). PCR reactions were carried out with 200 ng of genomic DNA in a total volume of 50 μL, containing 1.5 mmol/L Mg 2+ , 5μL 10× buffer, 0.02 μmol of each of the 4 dNTPs, 20 pmol of each of the primers, and 1.5 U of DNA polymerase. Thermal processing started with 95°C for 5 minutes, and 35 cycles at 94°C for 30 seconds, 58°C for 30 seconds, and 72°C for 30 seconds. This was followed by a final extension at 72°C for 10 minutes. All PCR reactions were carried out in a Perkin-Elmer 9600 thermal cycler (Foster City, CA); 20 μL of the PCR product was digested using the 5 U of the BstU1 restriction endonuclease (New England Biolabs, Beverly, MA) in 25 μL volumes at 37°C overnight. Digestion with BstU1 yields 100 and 22 bp fragments when A is at position 2350. The digestion products were then separated by electrophoresis on 4% agarose gel stained with ethidium bromide.
Statistical Analysis
All continuous variables were expressed as mean and standard deviation (SD). Student's t test and analysis of variance (ANOVA) followed by Newman-Keuls test were used to compare continuous variables from 2 groups and multiple groups, respectively. Genotype and allele frequencies were obtained by direct count. Differences in the distribution of alleles and genotypes between the groups and deviation from Hardy-Weinberg equilibrium were assessed using the χ 2 test. A binary logistic regression analysis was used for the evaluation of the independent effect of ACE genotypes on the development of acute MI, adjusted for the presence of risk factors. All significant tests were 2-tailed and were considered statistically significant at P < .05. SAS software (Version 8, SAS Institute, Cary, NC) was used in all statistical analyses.
Results
The clinical characteristics of the study participants are given in Table 1 . Compared with the controls, the MI group had more patients with a history of smoking and higher BMIs. The MI group also had significantly higher plasma levels of TC, LDL-C, TG, and ApoB and lower HDL-C levels than the controls. As is expected, higher serum levels of hs-CRP and sCD40L were found in the MI group than in the controls. Diastolic blood pressure was significantly lower in the MI group than in the controls, ACE Gene Polymorphism and AMI / Pan et al 437 which could be because of the result of medication in the patients after they were diagnosed. The frequency of the ACE 2350G>A polymorphism is shown in Table 2 . The genotype frequencies did not deviate significantly from those predicted by the Hardy-Weinberg equation for the 2 groups (P = .6792 and .3040 in the MI group and controls, respectively). The distribution of the ACE2350G>A genotypes (GG, GA, and AA) was 20.78%, 51.08%, and 28.14% in the MI group and 31.60%, 46.53%, and 21.87% in controls, respectively (P = .0167).The frequency of the A allele in the MI group was significantly higher than that in the control group (53.68% vs 45.14%, P = .0062). Compared with the wild type GG, the A allele carriers (GA + AA genotypes) had an approximately 2-fold increased MI risk (crude odds ratio [OR] = 1.76, 95% confidence interval [CI] = 1.24-3.52, P = .0057). After being adjusted for age, gender, BMI, smoking status, blood pressure, and plasma levels of lipids and apolipoproteins, the association persisted (adjusted OR = 1.58, 95% CI =1.10-2.26, P = .0114; Table 3 ).
The effects of the different genotypes on plasma/ serum lipids, apolipoproteins, hs-CRP, and sCD40L in the MI group and controls are shown in Table 4 . There were no significant differences in the lipid profiles among the 3 genotypes in the 2 groups. The hs-CRP and sCD40L values were also not statistically different among the genotypes.
The severity of coronary artery disease was assessed by using the number of vessels affected and morphological characteristics of the atherosclerotic plaque. No statistical difference was observed between ACE2350G>A polymorphism and the severity of coronary lesions (Table 5 ).
Discussion
ACE is a dipeptidyl carboxypeptidase I (EC.3.4.15.1) that activates angiotensin I through cleavage of the carboxyterminal dipeptide into the potent vasoconstrictor angiotensin II 19 and inactivates the vasodilator peptide bradykinin. 20 Elevated angiotensin II and decreased bradykinin promote smooth muscle cell growth and migration and macrophage activation and adhesion to the vascular wall. 21, 22 These changes may contribute to the development and progression of atherosclerotic plaques. In addition, angiotensin II may increase the risk of atherothrombosis by increasing platelet aggregation 23, 24 inducing the expression of plasminogen activator-inhibitor 1 and 2 and attenuating fibrinolytic activity in plasma. 25, 26 These experimental data were suggestive of a possible role of ACE in MI.
During the last decade there has been a growing interest in the study of the ACE gene I/D polymorphism as a potential risk factor for MI after Rigat et al 27 reported that more than half of the variance in plasma ACE levels is because of the influence of the I/D polymorphism. This polymorphism was initially reported to increase the risk for MI, 2 but subsequent studies yielded conflicting results. [4] [5] [6] [7] [8] The ACE gene I/D polymorphic locus, identified in a noncoding sequence, is more likely to serve as a genetic marker because of its LD with a putative disease-causing locus located nearby. 28 Zhu et al 14 genotyped 13 polymorphisms in the ACE gene in a Nigerian population performing linkage and association analysis; the 2350G>A polymorphism in exon 17 had the most significant effect on plasma ACE concentration, accounting for 19% of the total variance in ACE plasma levels. After adjustment for the effect of the ACE2350G>A polymorphism, the I/D polymorphism was no longer associated with ACE levels. The result implies that the I/D polymorphism is in LD with the 2350G>A polymorphism and unlikely to be a functional mutation.
In the present study, we first investigated the role of the ACE2350G>A polymorphism for the risk of acute MI in a Chinese population. Significant differences of the ACE2350G>A genotype and allele frequencies were found between patients with acute MI and controls. A allele carrier is an independent risk factor for acute MI after adjustments for age, gender, BMI, smoking status, blood pressure, and plasma levels of lipids and apolipoproteins. This result was not in agreement with the only reported study carried out in the Emirati population, 29 which showed no significant difference in distribution of the 3 genotypes between MI patients and controls (χ 2 = 3.1, P = .217). However, in their study, the ACE2350G>A genotypes were not in agreement with predicted Hardy-Weinberg equilibrium values, either in the normal control group or in acute MI patients.
One selection bias of retrospective case-control studies enrolling MI patients several months after the index event is the lack of representation of patients who died. To avoid the bias effect, we enrolled the majority of patients who experienced ACE Gene Polymorphism and AMI / Pan et al 439 death during hospitalization. However, bias caused by selection by death could not be entirely excluded, because patients who died before their admittance in the hospital could not have been included in this study. Control individuals in this study were free of disease and age-and gender-matched with the patients. As these control individuals had no evidence of MI, they represented a valid comparison group for these association studies, though it could not be predicted whether some of them would develop MI in the future. Dyslipidemia has been shown to be a risk factor for cardiovascular death and coronary heart disease in patients with or without a history of coronary artery disease. [30] [31] [32] In our study, the MI group had significantly higher plasma levels of TC, LDL-C, TG, and ApoB and lower HDL-C levels than the controls. But we didn't find any statistical differences in lipid profiles among the 3 genotypes (GG, GA, and AA) in the 2 groups.
Atherosclerosis is now described as an inflammatory disease and flared plaque inflammation is considered a cause of intimal erosion and rupture and, therefore, of acute ischemia. 33 Acute-phase reactants may play a pathophysiological role in atherosclerotic plaque instability, as reflected by elevated hs-CRP levels in the presence of ruptured coronary artery plaque. 34 The proinflammatory mediator CD40L plays a critical role in the cascade of proatherothrombotic functions thought to be important in the pathogenesis of acute coronary syndromes. These include augmented production of metalloproteinases, prothrombotic tissue factor, proinflammatory chemokines, cytokines, and cellular adhesion molecules and impaired regeneration of endothelial cells that may be particularly important after acute coronary syndromes. 35, 36 Whether a polymorphic change in the ACE gene could have any influence on hs-CRP or sCD40L level is unknown; therefore, we investigated whether there is any association between serum levels of hs-CRP or sCD40L and ACE2350G>A polymorphism. No significant differences between the 3 genotypes and serum levels of hs-CRP were found either in the acute MI group or in controls. Similarly, no association was observed between any of these 3 genotypes and serum sCD40L levels.
The present study showed that the ACE2350G>A polymorphism might have an association with MI; However, there was no remarkable association between ACE2350G>A polymorphism and the severity of coronary lesions. These results seem a little confusing but may be explained when the effects of vulnerable plaque on adverse coronary events are considered. It has been confirmed that plaque rupture is mainly determined by plaque vulnerability but not by the degree of coronary stenosis. The rupture of atheromatous plaque is regarded as the pathophysiological substrate of acute MI, and the process of plaque rupture is related to the intrinsic properties of individual plaque and the extrinsic factors acting on plaque, including sympathetic activity, intraluminal pressure, and vasoconstriction. 37 Diet et al 38 reported marked ACE accumulation in the region of inflammatory cells, especially in areas of clustered macrophages and T lymphocytes, which is considered to be a vulnerable part of plaque. Therefore, ACE2350G>A polymorphism might affect plaque vulnerability by increasing the plasma or tissue ACE activity.
In conclusion, our data support the hypothesis that ACE2350G>A polymorphism is associated with acute MI, and A allele carrier is an independent risk factor for acute MI in Chinese. Given the inherent limitations of this case-control study, whether the polymorphic change in the ACE gene could be a functional mutation or only a genetic marker is unknown. Further studies need to be carried out to determine the molecular mechanisms of this polymorphic change.
